VK2735 is a new medication currently under investigation for the treatment of obesity and overweight. The drug targets both the GLP-1 and GIP receptors. These naturally occurring hormones are involved in regulating appetite, satiety, and the metabolism of sugars and energy. The medication is being developed in two forms: an injection and a tablet. The tablet form may be particularly beneficial for individuals who prefer not to use injections. VK2735 remains in the clinical research phase and has not yet been approved or made available in the European Union. We will provide updates as soon as there are any developments.
Slimming
VK2735
Injection/tablet

In short
- For the treatment of overweight or obesity
- Not yet approved or available
- Injection or tablet with VK2735
- Potential average weight loss of up to 14.7% (injection) and 12.2% (tablet)
- Side effects appear similar to those of other GLP-1 medications
What is VK2735?
How VK2735 works
Side effects of VK2735
Research on VK2735
Status and availability of VK2735
What treatments are currently available?
Scientific sources
Related products
View other options that may suit you.










